Search Results - novel

48 Results

Sort By:

Novel Therapeutic Drug for Multiple Sclerosis

INVENTION NOVELTY This molecule, through its action on a unique target that is different from current therapeutic treatments for MS, has both immunosuppressive and neuromodulatory properties that will better prevent the progression of MS and repair the neuronal damage caused by the immune cells in MS. Currently, there are no MS drugs in the market...

Published: 5/2/2024 | Inventor(s): Paul Kim, Michael Kornberg, Peter Calabresi, Solomon Snyder

Keywords(s): Chronic Inflammatory Diseases, CNS and Neurological Disorders, Disease Indication, Multiple Sclerosis, Multiple Sclerosis (MS), Neurodegeneration, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Selective Targeting of a Novel Protective Anti-inflammatory Receptor in Human Mitochondria and its Role in Preserving Mitochondrial Functions

Unmet NeedAccording to WHO, over one billion people worldwide are living with elevated blood pressure which may lead to a range of adverse health conditions that cause ~1,100 deaths per day. Many current high blood pressure therapies focus on angiotensin receptor blocking drugs. Unfortunately, adverse events (e.g., renal dysfunction, hyperkalemia, and...

Published: 5/2/2024 | Inventor(s): Andrew Cheetham, Peter Abadir, Jeremy Walston, Honggang Cui

Keywords(s): Antagonists/Inhibitors, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

In vivo and in vitro Role of Lactosylceramide Synthase (LCS) in Angiogenesis and LCS (B1, 4GalT-V) as a Bio-marker for Human Colon Cancer

Description: C10539: Use of Biomarker for Colon Cancer Diagnosis Value Proposition: ADVANTAGES • Colon cancer biomarker is directly included in panels of biomarkers for use in needle biopsies of colon tissue for early detection and diagnosis. • Colon cancer is the second largest mortality after cardiovascular disease. 90% of colorectal cancers...

Published: 5/2/2024 | Inventor(s): Subroto Chatterjee

Keywords(s): Antagonists/Inhibitors, Biomarker, Cancers, Clinical Diagnostics, Colorectal Cancer, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Colorectal Cancer

Hexosamine Analogs for Regenerative Medicine and Diseases Associated with the Musculoskeletal System

Unmet Need:Osteoarthritis (OA) is the most common form of arthritis, affecting an estimated 32.5 million adults in the United States, with an increasing incidence as the population ages (see CDC) . OA is associated with considerable morbidity as a consequence of joint damage, resulting in pain, loss of joint range of motion, and disability. The disease...

Published: 5/2/2024 | Inventor(s): Kevin Yarema, Jennifer Elisseeff, Jeannine Coburn, Udayanath Aich

Keywords(s): Antagonists/Inhibitors, Arthritis, Biologics, Carbohydrates, Disease Indication, Drug Delivery Mechanism, Drug Delivery Vehicle, Joint Disorders, Novel, Osteoarthritis, Predicted Novelty, Single, Small Molecules, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Rheumatology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Rheumatology > Arthritis, Clinical and Disease Specializations > Rheumatology > Osteoarthritis

O‐substituted hydroxamic acids with pyrazolone leaving groups as novel physiologically useful HNO donors

#C14009Inventor(s): John Toscano, Saghar Nourian, Daryl Guthrie Unmet NeedAn estimated 17.9 million people died from cardiovascular diseases in 2019, representing 32% of all global deaths (see WHO). Nitroglycerin has been used as a vasodilator to treat heart conditions for over 130 years. It wasn't until 2003 that scientists realized the beneficial...

Published: 5/2/2024 | Inventor(s): John Toscano, Saghar Nourian, Daryl Guthrie

Keywords(s): Cardiovascular Diseases, Congestive Heart Failure, Congestive Heart Failure (CHF), Disease Indication, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Cardiovascular > Congestive Heart Failure

Design, Synthesis and Structure-activity Relationships of Pyridoquinazolinecarboxamides as RNA Polymerase I Inhibitors

This invention describes a set of novel small molecules that inhibit RNA polymerase I. RNA polymerase I (Pol I) governs the transcription of ribosomal RNAs, which are needed for building and function of the ribosomes. These ribosynthetic activities are greatly increased in cancer cells, and Pol I transcription rate is commonly deregulated in human cancers....

Published: 5/2/2024 | Inventor(s): Marikki Laiho, Sara Sanders, Laureen Colis, James Barrow, Glen Ernst

Keywords(s): Antagonists/Inhibitors, Cancers, Disease Indication, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

Rufinamide derivatives as novel drugs against epilepsy syndromes caused by aberrant sodium channel behavior

Unmet NeedLennox-Gastaut Syndrome (LGS) is rare and severe form of childhood-onset epilepsy associated with various types of seizures and cognitive dysfunction that persist into adulthood; yet, to date, LGS management is challenged by the lack of reliable diagnostic tests and potentially grave side-effects of available therapeutics. Rufinamide is a...

Published: 5/2/2024 | Inventor(s): Frank Bosmans, Dimpy Kalia

Keywords(s): Antagonists/Inhibitors, CNS and Neurological Disorders, Disease Indication, Epilepsy, Genetic Disorders, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Epilepsy, Clinical and Disease Specializations > Rare Diseases

Long Noncoding RNAs as Therapeutic and Diagnostic Markers for Childhood Cancer Medulloblastoma

Unmet NeedMedulloblastoma (MB) is the most common pediatric brain tumor and requires aggressive therapy in high-risk cases. MB is frequently resistant to treatment and is associated with high morbidity and mortality in affected individuals. There are four distinct molecular subgroups of MB (WNT, SHH, Group 3, and Group 4), which are characterized by...

Published: 5/2/2024 | Inventor(s): Ranjan Perera, Keisuke Katsushima

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, CNS and Neurological Disorders, Disease Indication, In Vitro Diagnostics (Old), Novel, Predicted Novelty, Target, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations > Oncology > Medulloblastoma, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Therapeutic Modalities > Targets

Inhibitors of Beta Lactamase

Unmet NeedDrug resistance to antibiotics, especially β-lactam antibiotics such as penicillin, cephalosporin and related compounds is one of the most serious problems in the treatment of infectious diseases. It represents not only a significant medical problem, but a major public health and economic burden. Reports from the Center for Disease Control...

Published: 5/2/2024 | Inventor(s): Samuel Milstein, Irene Luque, Xiao Yingxin, Raphael Ottenbrite, Patrick Ross, Ernesto Freire

Keywords(s): Antagonists/Inhibitors, Bacterial Infections, Disease Indication, Infectious Diseases, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases > Bacterial Infections

Discovery of 2,6-Dimethoxy-4-(5-Phenyl-4-Thiophen-2-yl-1H-Imidazol-2-yl)-Phenol (DPTIP) a Small Molecule Inhibitor of Neutral Sphingomyelinase 2 (nSMase2) for the Treatment of Neurodegenerative and Oncologic Diseases

Unmet NeedAlzheimer’s disease (AD) is the most common form of dementia, affecting approximately 5.7 million people in the United States in 2018. Yet, no cure exists for AD, and AD therapeutics presently on the market fail to treat the disease’s underlying causes. Recent studies in mice reveal that exosomes released from glial cells contribute to the...

Published: 5/2/2024 | Inventor(s): Barbara Slusher, Camilo Rojas, Ajit Thomas, Norman Haughey, Marc Ferrer, Xin Hu

Keywords(s): Antagonists/Inhibitors, Cancers, CNS and Neurological Disorders, Disease Indication, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules

1 2 3 4 5